U.S. Pharmacy Benefit Management Market Size, Share & Trends Analysis Report By Business Model (Standalone, Health Insurance Providers, Retail Pharmacy), By End Use (Commercial, Federal), And Segment - Industry Analysis, Share, Growth, Regional Outlook and Forecasts, 2023-2032

The U.S. pharmacy benefit management market size was exhibited at USD 483.9 billion in 2022 and is projected to hit around USD 1,122.65 billion by 2032, growing at a CAGR of  8.78% during the forecast period 2023 to 2032.

Key Takeaways:

• The standalone PBM segment held the largest revenue share of 38.19% in 2022.
• Based on end-use, the commercial segment accounted for the largest market share in 2022. The growth of the segment is attributed due to the proliferated usage of private insurance by the public and the increased cost of drugs
• In February 2022, Southern Scripts, one of the top PBM launched RxCompass, a new solution for mitigating the high cost of prescription drugs for companies and employees in the U.S.

U.S. Pharmacy Benefit Management Market Report Scope

The increase in healthcare expenditure has played a pivotal role in the development of the market. Besides this, the rising prevalence of chronic conditions and growing preference for vertical integration within pharmaceutical distribution systems have been augmenting the market in the country.

Pharmacy benefit managers function as intermediaries between insurance providers and pharmaceutical manufacturers. As per the National Association of Insurance Commissioners, around 66 PBM companies are operating in the U.S., controlling the pharmacy benefit of more than 266 million Americans. The demand for PBM (pharmacy benefit management) services is on the rise owing to an increase in the number of insurance providers with in-house pharmacy benefit groups to manage the covered population. PBM systems lower the overall costs by combining health plan customers to form bigger networks that enable negotiations and discounts.

The growth of the market is being driven by vertical integration, especially post two major alliances of CVS-Aetna and Cigna-Express Scripts. The supply chain dynamics are predicted to change considerably in the coming years, especially post these mergers. Partnerships of PBM organizations with health insurance companies are estimated to further benefit the growth of the market and the role of PBMs in the decision-making process. Such alliances in the market will improve the affordability and personalization of health insurance plans and provide more alternatives through better alignment with healthcare professionals.

The majority of drugs in the market offer similar mechanisms of action resulting in a minimal difference between APIs, ultimately increasing the price sensitivity of these drugs. PBMs release drug formularies that include all drugs covered under their benefit plans, wherein manufacturers are receptive to offering discounts. Manufacturers who add their drugs under the PBM formulary list significantly remunerate PBMs. This provides PBMs with an additional influence over prescribing decisions in the form of prior-authorization requirements, even allowing them to interrupt patient treatments.

The increasing prevalence of chronic diseases has increased the demand for treatment options. Therefore, some large pharmaceutical companies are focusing on producing expensive branded drugs. This has led to a significant increase in drug costs in recent years. For instance, a study published in Pharmaceutical Technology found that U.S. drug prices were raised by 2.0% in 2021, breaking the previous modest upward pattern. Further, according to SingleCare Administrators, single-prescription medicine prices were also raised by 6% in 2021.

Business Model Insights

The standalone PBM segment held the largest revenue share of 38.19% in 2022. Major players such as CVS Health and Express Scripts who underwent major mergers cater to this segment. Such mergers are anticipated to allow drug manufacturers to manage pricing policies and understand the pricing information of competitors. The market experienced consolidations between PBMs and health insurers leading to the strengthening of key players in the market.

PBM uses its scale to negotiate contracts between manufacturers and retailers, secure drug discounts, and determine which drugs qualify for various health care plans. Retail pharmacies are undertaking various strategic initiatives to include PBM services. For instance, in October 2019, Centene Corporation, Walgreens, and RxAdvance announced a strategic partnership to implement an innovative pharmacy management model aimed at increasing transparency, improving the customer experience, and ultimately delivering better healthcare outcomes at lower costs.

The health insurance providers segment is anticipated to expand owing to the increasing access to public health insurance and the rising number of people insured under commercial insurance. Due to the increasing number of beneficiaries, many payers prefer to have in-house PBM, which is driving segment growth. Furthermore, many insurers are acquiring PBMs or partnering with them to develop their own PBM platform. For instance, in December 2019, Humana announced the acquisition of Enclara Healthcare, a hospice PBM provider.

End-use Insights

The commercial segment held the maximum revenue and is estimated to dominate the market throughout the forecast period. The majority of U.S. employees are enrolled under commercial private insurance plans to benefit from the copay system for high-cost drugs. According to the Congressional Research Service, around 211 million people were covered by private insurance in 2020, combining group and non-group insurance.

Federal support is significant for government employees wherein premiums vary for different health plans and are paid in part by employers and employees. Employers usually pay up to 72.0% of the total amount in an average plan for self-only or family coverage while employees pay the rest. As per the Congressional Research Service, Medicaid covered 58 million people, Medicare covered 60 million people, and 12 million were covered under military insurance in 2020.

Key Companies & Market Share Insights

Some of the strategies undertaken by the market players to strengthen their market presence include mergers and acquisitions. A number of market participants are striving to implement strategic plans that are favoring demand. For instance, in October 2021, a nonprofit partnership of about 40 companies, including U.S. retailers Walmart (WMT.N) and Costco (COST.O), was created, forming a new company to provide pharmacy benefit management services for employers. Some of the prominent players in the U.S. pharmacy benefit management market include:

• CVS Health
• Cigna
• Optum, Inc.
• MedImpact
• Anthem
• Change Healthcare
• Prime Therapeutics LLC
• HUB International Limited.
• Elixir Rx Solutions LLC

Segments Covered in the Report

This report forecasts revenue growth at country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2032. For this study, Nova one advisor, Inc. has segmented the U.S. Pharmacy Benefit Management market.

By Business Model 

• Standalone PBM
• Health Insurance Providers
• Retail Pharmacy

By End-use 

• Commercial
• Federal